TOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced positive topline results from the global pivotal QuANTUM-First phase 3 trial evaluating quizartinib, a highly potent and selective FLT3 inhibitor, in patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML).1
QuANTUM-First met its primary endpoint, demonstrating that patients who received quizartinib in combination with standard induction and consolidation chemotherapy and then continued with single agent quizartinib had a statistically significant and clinically meaningful improvement in overall survival (OS) compared to those who received standard treatment alone. The safety of quizartinib was shown to be manageable and consistent with the known safety profile.
AML is one of the most common forms of leukemia in adults, representing about one-third of all cases.2 The five-year survival rate of AML is about 29%, and patients with FLT3-ITD positive AML have a particularly unfavorable prognosis, including an increased risk of relapse and shorter overall survival.1,3 There remains a high unmet need to improve survival for the majority of patients with AML.4
The results of the phase 3 QuANTUM-First trial showed that adding quizartinib, a potent and selective FLT3 inhibitor, to chemotherapy significantly prolonged overall survival in patients with newly diagnosed FLT3-ITD positive AML, said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. We look forward to sharing the QuANTUM-First data with the hematology community and will initiate discussions with global regulatory authorities.
Data from QuANTUM-First will be presented at an upcoming medical meeting and shared with regulatory authorities globally.
About QuANTUM-First
QuANTUM-First is a randomized, double-blind, placebo-controlled, multi-center global phase 3 study evaluating quizartinib in combination with standard induction and consolidation chemotherapy and then as continued single agent therapy in adult patients (age 18 75) with newly diagnosed FLT3-ITD positive AML.
Patients were randomized 1:1 into two treatment groups to receive quizartinib or placebo in combination with standard anthracycline and cytarabine-based induction and consolidation regimens. Eligible patients, including those who underwent allogenic hematopoietic stem cell transplant (HSCT), continued with single agent quizartinib or placebo for up to 36 cycles.
The primary study endpoint is OS. Secondary endpoints include event-free survival (EFS), post-induction rates of complete remission (CR) and composite complete remission (CRc), and the percentage of patients who achieve CR or CRc with FLT3-ITD minimal residual disease negativity. Safety and pharmacokinetics, along with exploratory efficacy and biomarker endpoints, were also evaluated.
QuANTUM-First enrolled 539 patients at approximately 200 study sites worldwide including in Asia, Europe, North America, Oceania and South America. For more information, visit ClinicalTrials.gov.
About Acute Myeloid Leukemia (AML)
More than 474,500 new cases of leukemia were reported globally in 2020 with more than 311,500 deaths.5 AML is one of the most common types of leukemia in adults, representing about one-third of all cases.2 A heterogenous blood cancer, AML is characterized by a five-year survival rate of about 29%, the lowest by far among the major leukemia subtypes.6,7
Treatment guidelines for patients with newly diagnosed AML recommend a cytarabine-based chemotherapy regimen with or without a targeted therapy as determined by the presence of genetic mutations, age and other factors.8 Patients with newly diagnosed FLT3 mutated AML may receive a FLT3 inhibitor as part of their initial treatment regimen and/or subsequent regimens.8 While intensive chemotherapy and/or HSCT can improve chances for sustained remission in eligible patients, a substantial proportion of patients are not suitable for either intervention, and cure rates are particularly low for older patients.1,6 In recent years, new targeted treatments have increased options and improved outcomes for some patients with molecularly defined AML subtypes.6
About FLT3-ITD
FLT3 (FMS-like tyrosine kinase 3) is a transmembrane receptor tyrosine kinase protein normally expressed by hematopoietic stem cells; FLT3 plays an important role in cell development by promoting cell survival, growth and differentiation through various signaling pathways.1 Mutations of the FLT3 gene, which occur in approximately 30% of patients with AML, can drive oncogenic signaling.1 The most common type of FLT3 mutation is the FLT3-ITD (internal tandem duplication), which is present in about 25% of all AML patients and contributes to cancer cell proliferation.1 Patients with FLT3-ITD mutations have a particularly unfavorable prognosis, including an increased risk of relapse and shorter overall survival.1
About Quizartinib
Quizartinib, an oral, highly potent and selective type II FLT3 inhibitor, is in phase 1/2 clinical development in pediatric and young adult patients with relapsed/refractory FLT3-ITD AML in Europe and North America.1 Several phase 1/2 combination studies with quizartinib are also underway at The University of Texas MD Anderson Cancer Center as part of a strategic research collaboration focused on accelerating development of Daiichi Sankyo pipeline therapies for AML.
Quizartinib is currently approved for use in Japan under the brand name VANFLYTA for the treatment of adult patients with relapsed/refractory FLT3-ITD AML, as detected by an approved test. Quizartinib is an investigational medicine in all countries outside of Japan.
About Daiichi Sankyo Oncology
The oncology portfolio of Daiichi Sankyo is powered by our team of world-class scientists that push beyond traditional thinking to create transformative medicines for people with cancer. Anchored by our DXd antibody drug conjugate (ADC) technology, our research engines include biologics, medicinal chemistry, modality and other research laboratories in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in the U.S. We also work alongside leading academic and business collaborators to further advance the understanding of cancer as Daiichi Sankyo builds towards our ambitious goal of becoming a global leader in oncology by 2025.
About Daiichi Sankyo
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose to contribute to the enrichment of quality of life around the world. In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an Innovative Global Healthcare Company Contributing to the Sustainable Development of Society. For more information, please visit http://www.daiichisankyo.com.
References
1 Daver N et al. Leukemia. (2019) 33:299312.2 American Cancer Society. Key Statistics for Acute Myeloid Leukemia. Updated January 2020.3 Leukemia and Lymphoma Society. Facts and Statistics. Leukemia: Survival (SEER Data for 2009-2015).4 Daver N et al. Blood Cancer Journal. (2020) 10:107.5 Global Cancer Observatory. Population Fact Sheet: World. Updated November 2020.6 Short et al. Cancer Discov. (2020);10:50625.7 Leukemia and Lymphoma Society. Facts and Statistics. Leukemia: Survival (SEER Data for 2009-2015).8 NCCN Practice Guidelines for Oncology. Acute Myeloid Leukemia. Version 3.2021 (March 2, 2021).
Go here to read the rest:
Quizartinib Added to Chemotherapy Demonstrates Superior Overall Survival Compared to Chemotherapy Alone in Adult Patients with Newly Diagnosed...
- The Stem Cell Center at Texas Heart Institute at St. Luke's [Last Updated On: August 22nd, 2014] [Originally Added On: August 22nd, 2014]
- The Ice Bucket Challenges stem cell controversy [Last Updated On: August 23rd, 2014] [Originally Added On: August 23rd, 2014]
- New gene editing method corrects muscular dystrophy in mice [Last Updated On: August 25th, 2014] [Originally Added On: August 25th, 2014]
- TD Jakes, Perry Noble, Nick Vujicic and Jentezen Franklin Accept ALS 'Ice Bucket Challenge,' Call Out Rick Warren, Ed ... [Last Updated On: August 30th, 2014] [Originally Added On: August 30th, 2014]
- Broach Foundation Commits $5 Million to Brain Cancer Research [Last Updated On: September 12th, 2014] [Originally Added On: September 12th, 2014]
- Could stem cell jab help elderly blind see again? [Last Updated On: October 15th, 2014] [Originally Added On: October 15th, 2014]
- UTA researcher uses microscaffolding injections to mend cartilage, prevent osteoarthritis [Last Updated On: October 31st, 2014] [Originally Added On: October 31st, 2014]
- 'Wound response' of cancer stem cells may explain chemo-resistance in bladder cancer [Last Updated On: December 4th, 2014] [Originally Added On: December 4th, 2014]
- Adult Stem Cell Banks and Clinics Marketing Stem Cell ... [Last Updated On: December 17th, 2014] [Originally Added On: December 17th, 2014]
- Howe shows steady progress following stem cell treatment [Last Updated On: December 20th, 2014] [Originally Added On: December 20th, 2014]
- Clinical Trials and Current Research at the Stem Cell ... [Last Updated On: December 24th, 2014] [Originally Added On: December 24th, 2014]
- Stem Cell Injection Houston | Stem Cell Houston Texas [Last Updated On: January 5th, 2015] [Originally Added On: January 5th, 2015]
- New Pathway for Stalling BRCA Tumor Growth Revealed [Last Updated On: February 3rd, 2015] [Originally Added On: February 3rd, 2015]
- Scientists Identify Prostate Cancer Stem Cells Among Low ... [Last Updated On: February 11th, 2015] [Originally Added On: February 11th, 2015]
- Fluorescent probe for labeling mitochondria helps scientists study fat-burning brown adipose tissue [Last Updated On: February 18th, 2015] [Originally Added On: February 18th, 2015]
- Xiling Shen: An Engineering Approach to Biomedical Challenges [Last Updated On: February 24th, 2015] [Originally Added On: February 24th, 2015]
- A single target for microRNA regulation [Last Updated On: March 3rd, 2015] [Originally Added On: March 3rd, 2015]
- CPRIT Awards Faculty $11.5 Million for Recruitment and Research in Brain and Bone Cancer, Biology, and Immunotherapy [Last Updated On: March 7th, 2015] [Originally Added On: March 7th, 2015]
- MD Anderson, Astellas Pharma sign option agreement for monoclonal antibody drug targeting acute myeloid leukemia [Last Updated On: April 3rd, 2015] [Originally Added On: April 3rd, 2015]
- Mesquite Texas Stem Cell Research | Mesquite TX Stem Cell ... [Last Updated On: July 2nd, 2015] [Originally Added On: July 2nd, 2015]
- Inducible Site-Specific Recombination in Neural Stem ... [Last Updated On: August 22nd, 2016] [Originally Added On: August 22nd, 2016]
- Why chemotherapy doesn't work - NaturalNews.com [Last Updated On: November 23rd, 2016] [Originally Added On: November 23rd, 2016]
- 7th International Conference on Stem Cells and Cancer ... [Last Updated On: November 27th, 2016] [Originally Added On: November 27th, 2016]
- Lung Institute | Stem Cell Treatment in Texas [Last Updated On: July 1st, 2017] [Originally Added On: July 1st, 2017]
- Texas gives green-light for experimental stem-cell ... [Last Updated On: July 1st, 2017] [Originally Added On: July 1st, 2017]
- Zika Virus Targets and Kills Brain Cancer Stem Cells - UC San Diego Health [Last Updated On: September 6th, 2017] [Originally Added On: September 6th, 2017]
- New therapy could protect diabetic bones - Science Magazine [Last Updated On: September 6th, 2017] [Originally Added On: September 6th, 2017]
- Army medic donates bone marrow to stranger in need - Hawaii Army Weekly [Last Updated On: September 8th, 2017] [Originally Added On: September 8th, 2017]
- Use of Genetically Modified Stem Cells in Experimental ... [Last Updated On: September 24th, 2017] [Originally Added On: September 24th, 2017]
- Rejuvenating gonads with stem cells - Fertility Lab Insider [Last Updated On: October 15th, 2017] [Originally Added On: October 15th, 2017]
- Kim Kardashian Micro Needling PRP with Stem Cells - Dermapen [Last Updated On: June 19th, 2018] [Originally Added On: June 19th, 2018]
- The Stem Cell Institute of Texas | San Antonio, TX [Last Updated On: July 6th, 2018] [Originally Added On: July 6th, 2018]
- Stem Cell Therapy Doctor | Westlake Austin Texas [Last Updated On: August 25th, 2018] [Originally Added On: August 25th, 2018]
- Shooting Up Stem Cells With Ben Greenfield The Down The ... [Last Updated On: September 16th, 2018] [Originally Added On: September 16th, 2018]
- HB810 | Right to Try Law | Texas Stem Cell Law | StemGenex [Last Updated On: October 13th, 2018] [Originally Added On: October 13th, 2018]
- Dallas, Texas, Stem Cells Treatment, Legal, Ft. Worth ... [Last Updated On: November 16th, 2018] [Originally Added On: November 16th, 2018]
- Texas | The Stem Cellar [Last Updated On: December 5th, 2018] [Originally Added On: December 5th, 2018]
- Four Types of Stem Cells - Texas Right to Life [Last Updated On: December 15th, 2018] [Originally Added On: December 15th, 2018]
- Stem Cell Doctor Dallas Dr. Darcy Brunk | Dallas, Plano ... [Last Updated On: January 25th, 2019] [Originally Added On: January 25th, 2019]
- Neuropathy & Pain Centers of Texas - Stem Cells & Neuropathy [Last Updated On: February 6th, 2019] [Originally Added On: February 6th, 2019]
- Stem Cell Treatment Center in Dallas, Texas | Stem Cell ... [Last Updated On: March 17th, 2019] [Originally Added On: March 17th, 2019]
- Our Doctors - Knee Stem Cells [Last Updated On: March 17th, 2019] [Originally Added On: March 17th, 2019]
- Stem Cell Rejuvenation Therapy | Totalhormonegenetherapy.com [Last Updated On: April 15th, 2019] [Originally Added On: April 15th, 2019]
- Fort Worth Stem Cells | Neuropathy and Pain Centers of Texas [Last Updated On: April 15th, 2019] [Originally Added On: April 15th, 2019]
- Houston, Texas Stem Cell Transplants, Richmond, Sugar Land ... [Last Updated On: April 21st, 2019] [Originally Added On: April 21st, 2019]
- Arlington Stem Cells | Neuropathy & Pain Centers of Texas [Last Updated On: May 1st, 2019] [Originally Added On: May 1st, 2019]
- Keller, TX Stem Cells | Neuropathy & Pain Centers of Texas [Last Updated On: May 31st, 2019] [Originally Added On: May 31st, 2019]
- Fast Facts: Stem Cells 101 Vital Record [Last Updated On: September 10th, 2019] [Originally Added On: September 10th, 2019]
- STEM CELL THERAPY & TREATMENTS Texas Regional Health [Last Updated On: September 10th, 2019] [Originally Added On: September 10th, 2019]
- Comparing Mymetics (OTCMKTS:MYMX) & Crispr Therapeutics (OTCMKTS:CRSP) - TechNewsObserver [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
- A breakthrough in the battle against citrus greening - Gainesville Sun [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
- Stem cells regrow leg's long bones - WNDU-TV [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
- Interview: BIOLIFE4D is The First US Company to Bioprint a Mini-Heart (for Cardiotoxicity Testing) - 3DPrint.com [Last Updated On: September 24th, 2019] [Originally Added On: September 24th, 2019]
- Nivolumab as an addition to frontline therapy of AML in younger patients - AML Global Portal [Last Updated On: September 24th, 2019] [Originally Added On: September 24th, 2019]
- Incoming Faculty Bring New Areas of Research to Rensselaer - Rensselaer Polytechnic Institute [Last Updated On: September 24th, 2019] [Originally Added On: September 24th, 2019]
- Drugs, Biologics, and Regenerative Medicine in 2019: A Successful Year Ends with Promise of a More Challenging 2020 - JD Supra [Last Updated On: December 18th, 2019] [Originally Added On: December 18th, 2019]
- El Paso scientists team up for heart research project at the International Space Station - KVIA El Paso [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- Stem Cell Therapy for Joints & Spine in Austin Texas [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- El Paso scientists to deliver 3D bioprinted miniature hearts to the ISS - 3D Printing Industry [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- Recombinetics Announces Collaboration with University of Texas Southwestern to Advance Regenerative Medicine Through Therapeutic Cell, Tissue, and... [Last Updated On: February 27th, 2020] [Originally Added On: February 27th, 2020]
- Cumberland County family turns to non-FDA approved stem cell treatment to help two-year-old son with cerebral palsy - FOX43.com [Last Updated On: February 27th, 2020] [Originally Added On: February 27th, 2020]
- What to do in Madison: March 2-8, 2020 - The Bozho [Last Updated On: March 2nd, 2020] [Originally Added On: March 2nd, 2020]
- Texas A&M Researcher Named To National List Of Inspiring Black Scientists - Texas A&M University [Last Updated On: March 2nd, 2020] [Originally Added On: March 2nd, 2020]
- Jimbo Fisher's Kidz1stFund, Aggie Corps of Cadets team up for Be the Match bone marrow donor registry drive - Bryan-College Station Eagle [Last Updated On: March 2nd, 2020] [Originally Added On: March 2nd, 2020]
- How industry hopes to take on COVID-19 - Bioprocess Insider - BioProcess Insider [Last Updated On: March 8th, 2020] [Originally Added On: March 8th, 2020]
- Meng Hsieh, Andrew Shubin - The New York Times [Last Updated On: March 8th, 2020] [Originally Added On: March 8th, 2020]
- Pfizer, NYU working on innovative coronavirus vaccine that could be ready by end of summer - NBC News [Last Updated On: May 7th, 2020] [Originally Added On: May 7th, 2020]
- South Sound Community Bands Together To Save Local Lives - southsoundtalk.com [Last Updated On: May 7th, 2020] [Originally Added On: May 7th, 2020]
- UT Student Awarded Prestigious Astronaut Scholarship - UT News | The University of Texas at Austin [Last Updated On: June 9th, 2020] [Originally Added On: June 9th, 2020]
- FTC ramps up enforcement with new wave of warning letters - NutraIngredients-usa.com [Last Updated On: June 9th, 2020] [Originally Added On: June 9th, 2020]
- Who's to blame? These three scientists are at the heart of the Surgisphere COVID-19 scandal - Science Magazine [Last Updated On: June 9th, 2020] [Originally Added On: June 9th, 2020]
- Texas Stem Cell Law Opens Door for Controversial Treatments [Last Updated On: June 11th, 2020] [Originally Added On: June 11th, 2020]
- Tau: Why Alzheimer's Worsens Fast in Some, Slowly in Others - Alzforum [Last Updated On: June 23rd, 2020] [Originally Added On: June 23rd, 2020]
- Scholarly Perspectives on COVID-19, Part 1: This Was Only a Matter of Time - Southern Newsroom [Last Updated On: June 23rd, 2020] [Originally Added On: June 23rd, 2020]
- New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Combination Therapy with BeyondSpring's Plinabulin - BioSpace [Last Updated On: June 23rd, 2020] [Originally Added On: June 23rd, 2020]
- STEM CELLS | VitaDrip IV Therapy | Texas [Last Updated On: June 26th, 2020] [Originally Added On: June 26th, 2020]
- Biotechnology could change the cattle industry. Will it succeed? - Salon [Last Updated On: September 8th, 2020] [Originally Added On: September 8th, 2020]
- Reliable tumor detection by whole-genome methylation sequencing of cell-free DNA in cerebrospinal fluid of pediatric medulloblastoma - Science... [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- Five Indian American Researchers Named Among NIH 2020 New Innovator Awardees - India West [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- Dr. Daisy Ayim, Cosmetic Surgeon, ObGyn, Business Owner and Entrepreneur, Is Revolutionizing The Integration Of Women's Health And Cosmetic Care -... [Last Updated On: October 31st, 2020] [Originally Added On: October 31st, 2020]